<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938572</url>
  </required_header>
  <id_info>
    <org_study_id>NN1406-4218</org_study_id>
    <secondary_id>2014-005340-18</secondary_id>
    <secondary_id>U1111-1164-6715</secondary_id>
    <nct_id>NCT02938572</nct_id>
  </id_info>
  <brief_title>A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate Pharmacodynamics
      (the effect of the investigated drug on the body) , Pharmacokinetics (the exposure of the
      trial drug in the body), and Safety of NNC0143-0406 in Subjects with Type 1 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2016</start_date>
  <completion_date type="Actual">July 4, 2017</completion_date>
  <primary_completion_date type="Actual">June 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of suppression of endogenous glucose production relative to total glucose lowering effect</measure>
    <time_frame>Two weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Time of first trial product administration to 7 days (7 times 24 hours) after last trial product administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>NNC0143-0406</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0143-0406</intervention_name>
    <description>Administered subcutaneously (s.c. under the skin)</description>
    <arm_group_label>NNC0143-0406</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Administered subcutaneously (s.c. under the skin)</description>
    <arm_group_label>Insulin aspart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18âˆ’55 years (both inclusive) at the time of signing informed
             consent

          -  Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior
             to the day of screening

          -  Treated with continuous subcutaneous insulin infusion at least 90 days prior to the
             day of screening

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product(s) or related products

          -  Males who are sexually active and not surgically sterilised (vasectomy or otherwise)
             and their partners that are not using a highly effective contraception method, from
             randomisation until 90 days after dosing, such as double barrier contraception (e.g.
             condom and spermicide) or combination of either an oral ontraceptive, a contraceptive
             patch, a diaphragm or intrauterine device, together with a physical barrier such as
             condom. Male subjects must also agree to refrain from sperm donation from
             randomisation until 90 days after last dosing

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using adequate contraceptive methods (adequate
             contraceptive measures as required by local regulation or practice) (adequate
             contraceptive measures are defined as sterilisation, hormonal intrauterine device,
             oral contraceptives, condom with spermicide sexual abstinence or vasectomised partner)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

